|
市場調査レポート
商品コード
1105810
帯状疱疹ワクチンの中国市場(2022年~2031年)Investigation Report on China's Shingles Vaccine Market 2022-2031 |
||||||
帯状疱疹ワクチンの中国市場(2022年~2031年) |
出版日: 2022年07月25日
発行: China Research and Intelligence
ページ情報: 英文 40 Pages
納期: 即日から翌営業日
|
2020年に帯状疱疹ワクチンが中国市場に参入して以来、帯状疱疹ワクチンの年間売上高は1,900万人民元(285万米ドル)に達し、年間販売数量は約1万2,000人分に達しています。2022年~2031年の間に市場は拡大し、売上高は引き続き増加すると予測されます。
当レポートでは、中国の帯状疱疹ワクチン市場について調査分析し、COVID-19の影響、市場規模、メーカー分析、市場の見通しなどの情報を提供しています。
The trade name of shingles vaccine (recombinant zoster vaccine) is SHINGRIX, which was developed by GlaxoSmithKline. Its product was firstly approved in China in 2020. Shingles vaccine is suitable for adults aged 50 years and over to protect against shingles (herpes zoster). The recombinant zoster vaccine has been listed in the Chinese market. By July 2022, GlaxoSmithKline Biologicals is the only manufacturer in the Chinese Shingles Vaccine market.
According to CRI's market research, since Shingles Vaccine entered the Chinese market in 2020, its annual sales value reached CNY19 million(US$2.85 million), and its annual sales volume reached nearly 12,000 doses. Therefore, the development prospects are quite good.
According to CRI analysis, from 2022 to 2031, as Shingles Vaccine market expands, its sales will continue to grow. Compared with Merck's Zostavax, SHINGRIX has better preventive effects and faster replacement velocity. Therefore, as the market share of Shingles Vaccine will gradually increase, and sales and sales volume will also increase.
Topics covered: